Literature DB >> 28234737

Bacterial Infections in Children With Acute Myeloid Leukemia Receiving Ciprofloxacin Prophylaxis.

Suha Al Omar1, Nadine Anabtawi, Wiam Al Qasem, Rawad Rihani.   

Abstract

BACKGROUND: The aim of the study was to describe the incidence and type of bacterial infections associated with the use of ciprofloxacin prophylaxis as single agent in pediatric patients with acute myeloid leukemia (AML). PROCEDURE: This was a retrospective review of all patients with AML, who were treated according to the AML02 protocol between 2011 and 2015. The medical records were reviewed for any positive cultures from the initiation of the protocol until death or protocol discontinuation. Patient demographics, type of infections, type of isolated bacteria, and intensive care unit admissions were recorded.
RESULTS: A total of 50 patients were evaluated, who were of a mean age of 8 years±5.1 (SD). We identified 77 episodes of bacterial infections in 42 (84%) patients. Among those bacterial infections, 73 episodes were with bacteremia and included 45 (62%) gram-positive bacterial infections, 24 (33%) gram-negative bacterial infections, and 4 (6%) mixed gram-negative and gram-positive bacterial infections. Coagulase-negative Staphylococcus and Viridans streptococci were the most commonly isolated bacteria in 33% and 30% of the episodes, respectively. Seventeen (45%) patients with bacteremia required intensive care unit admission.
CONCLUSIONS: A high rate of bacterial infection was detected in patients who received the AML02 protocol, mainly gram-positive bacterial infections. The prophylactic regimen should be reconsidered for its efficacy, and other antibacterial prophylaxis may be used.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28234737     DOI: 10.1097/MPH.0000000000000792

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  5 in total

1.  Cost-effectiveness of levofloxacin prophylaxis against bacterial infection in pediatric patients with acute myeloid leukemia.

Authors:  Meghan McCormick; Erika Friehling; Ramasubramanian Kalpatthi; Nalyn Siripong; Kenneth Smith
Journal:  Pediatr Blood Cancer       Date:  2020-07-25       Impact factor: 3.167

2.  Adverse Effects of Intravenous Vancomycin-Based Prophylaxis during Therapy for Pediatric Acute Myeloid Leukemia.

Authors:  Yilun Sun; Rachael L Huskey; Li Tang; Hiroto Inaba; Aditya H Gaur; Raul Ribeiro; Jeffrey E Rubnitz; Joshua Wolf
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

3.  Effect of Antibacterial Prophylaxis on Febrile Neutropenic Episodes and Bacterial Bloodstream Infections in Dutch Pediatric Patients with Acute Myeloid Leukemia: A Two-Center Retrospective Study.

Authors:  Romy E Van Weelderen; Kim Klein; Bianca F Goemans; Wim J E Tissing; Tom F W Wolfs; Gertjan J L Kaspers
Journal:  Cancers (Basel)       Date:  2022-06-28       Impact factor: 6.575

Review 4.  Antimicrobial Prophylaxis and Modifications of the Gut Microbiota in Children with Cancer.

Authors:  Gianluca Bossù; Riccardo Di Sario; Alberto Argentiero; Susanna Esposito
Journal:  Antibiotics (Basel)       Date:  2021-02-03

Review 5.  Antibacterial prophylaxis in pediatric patients with leukemia.

Authors:  Suha Al Omar; Deema Moumani; Rawad Rihani
Journal:  Saudi Pharm J       Date:  2018-04-03       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.